辉瑞、拜耳折戟,阿斯利康、百济神州等看好,这个靶点潜力何在?

Insight数据库
19 Mar

IRAK4 因在 Toll 样受体(TLR)信号转导和先天免疫反应中起着关键作用,被视为自身免疫病、血液瘤的潜力靶点。然而,IRAK4 靶向药物的开发并不顺利,辉瑞、拜耳等公司的 IRAK4 小分子抑制剂临床曾接连失利,凸显了该靶点药物开发的难度。不过,IRAK4 的潜力并没有因此被忽视。根据 Insight 数据库,目前全球范围内已有 15 款 IRAK4 候选药物进入临床阶段(仅统计活跃状态)...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10